Performance analysis of Evoke Pharma (EVOK)
Annual Return
Over the past 3 years, EVOK has had an average annual return of -20.68%, underperforming the benchmark SPY, which returned +21.07% annual.
Over the past 5 years, EVOK has had an average annual return of -46.42%, underperforming the benchmark SPY, which returned +12.33% annual.
Over the past 10 years, EVOK has had an average annual return of -36.19%, underperforming the benchmark SPY, which returned +14.77% annual.
Since Sep 25, 2013, EVOK has had an average annual return of -33.74%, underperforming the benchmark SPY, which returned +13.86% annual.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +150% | -65.33% | -60.53% | -59.40% | -78.71% | +59.28% | -34.66% | +9.71% | +11.85% | -38.78% | -44.07% | -20.80% |
| 2013 | |||||||||||
| -36.54% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +11.54% | -3.45% | -42.86% | +0% | +31.25% | -28.57% | +40% | +52.38% | -9.38% | +3.45% | +113.33% | +1.56% | +150% |
| 2024 | -36.00% | -2.08% | -8.51% | -25.58% | +6.25% | +11.76% | -26.32% | -10.71% | +12% | +25% | -25.71% | -0% | -65.33% |
| 2023 | +51.05% | -27.87% | -34.78% | -1.48% | -11.28% | -0.85% | -1.71% | -23.48% | +11.36% | -16.33% | +12.20% | -18.48% | -60.53% |
| 2022 | -0.85% | +17.03% | -22.28% | -5.21% | -52.25% | +20.42% | -6.09% | -11.11% | -30.73% | -7.52% | -13.82% | +79.25% | -59.40% |
| 2021 | -0% | +14.33% | -37.96% | -11.48% | -24.06% | +11.35% | -18.25% | +4.51% | +11.03% | -5.33% | -38.26% | -27.67% | -78.71% |
| 2020 | -14.20% | -11.49% | -5.73% | +14.68% | +85.70% | +43.30% | +4.25% | +21.13% | +4.94% | -18.55% | -18.32% | -17.31% | +59.28% |
| 2019 | +16.57% | +6.58% | -51.30% | -52.03% | -12.07% | -1.30% | +56.02% | +2.05% | -13.46% | +1.64% | +89.80% | -2.40% | -34.66% |
| 2018 | +18.60% | -27.24% | +6.68% | +19.19% | +18.56% | -14.98% | +10.80% | +4.37% | +3.09% | -18.12% | +4.52% | -2.76% | +9.71% |
| 2017 | +39.11% | +17.04% | -5.75% | -11.97% | -9.63% | +3.71% | -11.66% | +11.53% | +32.51% | -8.68% | -12.47% | -15.35% | +11.85% |
Drawdown analysis of Evoke Pharma (EVOK)
The maximum drawdown for the EVOK was -99.90%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current EVOK drawdown is -99.45%.
Since Sep 25, 2013 EVOK has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.90% | Oct 4, 2013 | 2894 | Apr 8, 2025 | Ongoing | Ongoing | Ongoing |
| -0.66% | Sep 30, 2013 | 1 | Oct 1, 2013 | 2 | Oct 3, 2013 | 3 |
| -0.34% | Sep 25, 2013 | 1 | Sep 26, 2013 | 1 | Sep 27, 2013 | 2 |